Rankings
▼
Calendar
INDV Q4 2024 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena
INDV
Indivior Pharmaceuticals Inc
$4B
Q4 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$299M
+2.0% YoY
Gross Profit
$276M
92.3% margin
Operating Income
$96M
32.1% margin
Net Income
$59M
19.7% margin
EPS (Diluted)
$0.45
QoQ Revenue Growth
-2.6%
Cash Flow
Operating Cash Flow
-$6M
Free Cash Flow
-$21M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$1.7B
Stockholders' Equity
-$348M
Cash & Equivalents
$319M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$299M
$293M
+2.0%
Gross Profit
$276M
$242M
+14.0%
Operating Income
$96M
$61M
+57.4%
Net Income
$59M
$54M
+9.3%
← FY 2024
All Quarters
Q1 2025 →